Study identifier:SD-005-0414
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the effect of Long-term treatment with Rhinocort Aqua (Budesonide) Nasal Spray in Children with Perennial Allergic Rhinitis.
Perennial Allergic Rhinitis
Phase 4
No
Budesonide, Placebo
All
209
Interventional
4 Years - 10 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Budesonide | - |
Placebo Comparator: 2 | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.